Isabelle van Rycke
Chief Executive Officer at Upsa Belgium SA
Profile
Isabelle van Rycke is currently the Chairman & Co-Chief Executive Officer at UPSA SAS and the Co-Managing Director & Director at UPSA Belgium SA.
Isabelle van Rycke active positions
| Companies | Position | Start |
|---|---|---|
Upsa Belgium SA
 Upsa Belgium SA Medical DistributorsDistribution Services UPSA Belgium SA wholesales pharmaceutical products. The private company is based in Etterbeek, Belgium. The CEOs are Isabelle van Rycke, Jun Kuroda. The Belgian company was founded in 2019. | Chief Executive Officer | 2021-06-30 |
UPSA SAS
 UPSA SAS Pharmaceuticals: MajorHealth Technology Part of Taisho Pharmaceutical Holdings Co., Ltd., UPSA SAS is a pharmaceutical laboratory that specializes in effervescence, pain treatment, ENT disorders, vitality, digestion, and sleep quality. The company is based in Rueil-Malmaison, France. The CEOs of the French company are Anthony Lallier and Isabelle van Rycke. UPSA was acquired by Taisho Pharmaceutical Co., Ltd. from Bristol Myers Squibb Co. on July 01, 2019 for $1,465.24 million. | Chief Executive Officer | 2021-04-30 |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Upsa Belgium SA
Upsa Belgium SA Medical DistributorsDistribution Services UPSA Belgium SA wholesales pharmaceutical products. The private company is based in Etterbeek, Belgium. The CEOs are Isabelle van Rycke, Jun Kuroda. The Belgian company was founded in 2019. | Distribution Services |
UPSA SAS
UPSA SAS Pharmaceuticals: MajorHealth Technology Part of Taisho Pharmaceutical Holdings Co., Ltd., UPSA SAS is a pharmaceutical laboratory that specializes in effervescence, pain treatment, ENT disorders, vitality, digestion, and sleep quality. The company is based in Rueil-Malmaison, France. The CEOs of the French company are Anthony Lallier and Isabelle van Rycke. UPSA was acquired by Taisho Pharmaceutical Co., Ltd. from Bristol Myers Squibb Co. on July 01, 2019 for $1,465.24 million. | Health Technology |
- Stock Market
- Insiders
- Isabelle van Rycke
